Malaria vaccine development 2

Published on June 22, 2015   46 min

Other Talks in the Series: Vaccines

Please wait while the transcript is being prepared...
So that completes the first part of the talk, the introduction. Now I'm going to go down into vaccine development efforts in three main sections. I'm going to focus initially on our community vaccine development goals, I expressed that there clearly is an unmet medical need in malaria for a vaccine. But it's very important that we target our vaccine development efforts in an appropriate way to develop the type of tools that the community is going to need to help mitigate the burden of malaria going forward. And then I added a few slides on increasing the probability of success in reducing risk. We're in a very resource-constrained environment in terms of malaria product development. These vaccines are intended for the poorest of the poor. There's not a high profit to be made in developing these types of vaccines. We're targeting the parasite here, very difficult to develop vaccines against parasites. There are currently no licensed vaccines against human parasites. So this is challenging work. The payoffs are modest. The risk is high. So we have to be very prudent in terms of how we use the limited resources and make sure that we're doing everything we can early in development to reduce risk and ensure that we're only investing in candidates that have the highest possible probability of success. And I'm going to touch on that a little bit in the next few slides. We have some great tools in malaria vaccine development that really do put us at an advantage, and I think give us a great confidence that we will be able to develop highly effective vaccines over the coming years. And then to finish, I will talk about the progress against these community goals as things stand today, with a particular emphasis on these tools that we use to make the most robust decisions that we can going forward.